Jump to Main Content
Integrated Metabolomics and Lipidomics Analyses Reveal Metabolic Reprogramming in Human Glioma with IDH1 Mutation
- Zhou, Lina, Wang, Zhichao, Hu, Chunxiu, Zhang, Chaoqi, Kovatcheva-Datchary, Petia, Yu, Di, Liu, Shasha, Ren, Feifei, Wang, Xiaolin, Li, Yanli, Hou, Xiaoli, Piao, Hailong, Lu, Xin, Zhang, Yi, Xu, Guowang
- Journal of proteome research 2018 v.18 no.3 pp. 960-969
- genome, glioblastoma, glycolysis, humans, isocitrate dehydrogenase, lipid metabolism, long-chain-fatty-acid-CoA ligase, metabolomics, mutants, mutation, patients, protein synthesis, proteome, pyruvic acid, sequence analysis, sphingolipids, triacylglycerols, tricarboxylic acid cycle
- Mutations in isocitrate dehydrogenase (IDH) 1 are high-frequency events in low-grade glioma and secondary glioblastoma, and IDH1 mutant gliomas are vulnerable to interventions. Metabolic reprogramming is a hallmark of cancer. In this study, comprehensive metabolism investigation of clinical IDH1 mutant glioma specimens was performed to explore its specific metabolic reprogramming in real microenvironment. Massive metabolic alterations from glycolysis to lipid metabolism were identified in the IDH1 mutant glioma tissue when compared to IDH1 wild-type glioma. Of note, tricarboxylic acid (TCA) cycle intermediates were in similar levels in both groups, with more pyruvate found entering the TCA cycle in IDH1 mutant glioma. The pool of fatty acyl chains was also reduced, displayed as decreased triglycerides and sphingolipids, although membrane phosphatidyl lipids were not changed. The lower fatty acyl pool may be mediated by the lower protein expression levels of long-chain acyl-CoA synthetase 1 (ACSL1), ACSL4, and very long-chain acyl-CoA synthetase 3 (ACSVL3) in IDH1 mutant glioma. Lower ACSL1 was further found to contribute to the better survival of IDH1 mutant glioma patients based on the The Cancer Genome Atlas (TCGA) RNA sequencing data. Our research provides valuable insights into the tissue metabolism of human IDH1 mutant glioma and unravels new lipid-related targets.